Nader Francois
- SEC CIK
- 0001365343
No open-market purchases or sales filed in the past year.
Current role at each company
- MRNA Moderna, Inc.Directoras of May 8, 2026
- TECX Tectonic Therapeutic, Inc.Directoras of Apr 3, 2026
- TRML Tourmaline Bio, Inc.Directoras of Jun 14, 2023
- XLRN Acceleron Pharma IncDirectoras of Nov 22, 2021
- ALXN Alexion Pharmaceuticals, Inc.Directoras of Jul 23, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Nader Francois as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
TRML Tourmaline Bio, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 13, 2022 (view filing) | Jul 19-21 | 56 days | Nader FrancoisDirector | PPurchase | +138.5K | $3.61 | +$500.0K | New position138.5K after | Amended3 lots |
MRNA Moderna, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 12, 2022 (view filing) | May 10 | 2 days | Nader FrancoisDirector | SSale | −3.20K | $136.10 | −$435.0K | −13.4%20.6K after |